Literature DB >> 7650723

Role of exotoxin A in inducing severe Pseudomonas aeruginosa infections in mice.

S Miyazaki1, T Matsumoto, K Tateda, A Ohno, K Yamaguchi.   

Abstract

The effects of exotoxin A (EXA) from Pseudomonas aeruginosa on polymorphonuclear leucocytes (PMNLs) were studied in a mouse model and in vitro. P. aeruginosa PA103, which produced EXA, was 20 times more virulent for normal mice than was its EXA-deficient mutant, PA103-29. EXA was detected in the plasma of mice infected with P. aeruginosa PA103, and its presence correlated with increasing numbers of bacteria in the blood and internal organs. A monoclonal antibody (MAb) against EXA prevented the death of the mice if it was given simultaneously with, or 2 h before, infection with strain PA103. The number of PMNLs in murine blood decreased by 50% within 30 min of intravenous injection of EXA, but this decrease was prevented by simultaneous or prior injection of MAb to the toxin. EXA inhibited in-vitro phagocytosis and killing of P. aeruginosa by human and murine PMNLs and decreased the number of the PMNLs by between 60 and 68%. Collectively, these results not only confirm that EXA is toxic in vivo, but also suggest that this toxin accelerates the growth of virulent P. aeruginosa in mice.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7650723     DOI: 10.1099/00222615-43-3-169

Source DB:  PubMed          Journal:  J Med Microbiol        ISSN: 0022-2615            Impact factor:   3.196


  17 in total

Review 1.  Role of pore-forming toxins in bacterial infectious diseases.

Authors:  Ferdinand C O Los; Tara M Randis; Raffi V Aroian; Adam J Ratner
Journal:  Microbiol Mol Biol Rev       Date:  2013-06       Impact factor: 11.056

2.  Cooperation between LepA and PlcH contributes to the in vivo virulence and growth of Pseudomonas aeruginosa in mice.

Authors:  Yutaka Kida; Takashi Shimizu; Koichi Kuwano
Journal:  Infect Immun       Date:  2010-11-01       Impact factor: 3.441

Review 3.  Natural pathogens of laboratory mice, rats, and rabbits and their effects on research.

Authors:  D G Baker
Journal:  Clin Microbiol Rev       Date:  1998-04       Impact factor: 26.132

Review 4.  Peptide therapeutics for treating ocular surface infections.

Authors:  Curtis R Brandt
Journal:  J Ocul Pharmacol Ther       Date:  2014-09-24       Impact factor: 2.671

Review 5.  Pseudomonas aeruginosa virulence and therapy: evolving translational strategies.

Authors:  Jeffrey L Veesenmeyer; Alan R Hauser; Thiago Lisboa; Jordi Rello
Journal:  Crit Care Med       Date:  2009-05       Impact factor: 7.598

6.  The transition metal gallium disrupts Pseudomonas aeruginosa iron metabolism and has antimicrobial and antibiofilm activity.

Authors:  Yukihiro Kaneko; Matthew Thoendel; Oyebode Olakanmi; Bradley E Britigan; Pradeep K Singh
Journal:  J Clin Invest       Date:  2007-03-15       Impact factor: 14.808

7.  Host translational inhibition by Pseudomonas aeruginosa Exotoxin A Triggers an immune response in Caenorhabditis elegans.

Authors:  Deborah L McEwan; Natalia V Kirienko; Frederick M Ausubel
Journal:  Cell Host Microbe       Date:  2012-04-19       Impact factor: 31.316

8.  A dominant-negative approach that prevents diphthamide formation confers resistance to Pseudomonas exotoxin A and diphtheria toxin.

Authors:  Vincent Roy; Karim Ghani; Manuel Caruso
Journal:  PLoS One       Date:  2010-12-23       Impact factor: 3.752

9.  Intranasal immunization strategy to impede pilin-mediated binding of Pseudomonas aeruginosa to airway epithelial cells.

Authors:  Jennifer C Hsieh; Doris M Tham; Weijun Feng; Fan Huang; Selamawit Embaie; Keyi Liu; Deborah Dean; Ralf Hertle; David J Fitzgerald; Randall J Mrsny
Journal:  Infect Immun       Date:  2005-11       Impact factor: 3.609

10.  alpha1-Antitrypsin Portland, a bioengineered serpin highly selective for furin: application as an antipathogenic agent.

Authors:  F Jean; K Stella; L Thomas; G Liu; Y Xiang; A J Reason; G Thomas
Journal:  Proc Natl Acad Sci U S A       Date:  1998-06-23       Impact factor: 12.779

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.